Lipella Pharmaceuticals (NASDAQ:LIPO – Get Rating) and TG Therapeutics (NASDAQ:TGTX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Earnings & Valuation
This table compares Lipella Pharmaceuticals and TG Therapeutics’ revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lipella Pharmaceuticals | $180,000.00 | 60.91 | -$2.60 million | N/A | N/A |
| TG Therapeutics | $2.79 million | 1,445.81 | -$198.34 million | ($1.23) | -21.95 |
Lipella Pharmaceuticals has higher earnings, but lower revenue than TG Therapeutics.
Insider and Institutional Ownership
Profitability
This table compares Lipella Pharmaceuticals and TG Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lipella Pharmaceuticals | N/A | N/A | N/A |
| TG Therapeutics | -1,966.56% | -213.67% | -78.35% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Lipella Pharmaceuticals and TG Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lipella Pharmaceuticals | 0 | 0 | 0 | 0 | N/A |
| TG Therapeutics | 2 | 0 | 4 | 0 | 2.33 |
TG Therapeutics has a consensus target price of $18.67, indicating a potential downside of 30.86%. Given TG Therapeutics’ higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Lipella Pharmaceuticals.
Summary
TG Therapeutics beats Lipella Pharmaceuticals on 6 of the 10 factors compared between the two stocks.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella Pharmaceuticals Inc. is based in PITTSBURGH.
About TG Therapeutics
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
